Literature DB >> 22271116

Clinical significance of global two-dimensional strain as a surrogate parameter of myocardial fibrosis and cardiac events in patients with hypertrophic cardiomyopathy.

Makoto Saito1, Hideki Okayama, Toyofumi Yoshii, Haruhiko Higashi, Hiroe Morioka, Go Hiasa, Takumi Sumimoto, Shinji Inaba, Kazuhisa Nishimura, Katsuji Inoue, Akiyoshi Ogimoto, Yuji Shigematsu, Mareomi Hamada, Jitsuo Higaki.   

Abstract

AIMS: Late gadolinium enhancement (LGE) on contrast-enhanced magnetic resonance imaging (MRI) in hypertrophic cardiomyopathy (HCM) has been reported to be associated with myocardial fibrosis and cardiac events. In patients with HCM, two-dimensional (2D) strain can identify subclinical global systolic dysfunction despite normal left ventricular (LV) chamber function. Therefore, this study tested the hypothesis that global 2D strain could detect subtle myocardial fibrosis and serve as a novel prognostic parameter in HCM patients. METHODS AND
RESULTS: Echocardiography and MRI were performed in 48 consecutive patients with HCM and normal chamber function. We measured global longitudinal strain (GLS) in apical two-chamber, four-chamber, and long-axis views using speckle-tracking analysis. The extent of LGE (%LGE = LGE volume/total LV volume) and LV mass index were calculated by MRI using Simpson's rule and custom software. All patients were followed up for major cardiac events. Global longitudinal strain in patients with LGE was significantly lower than that without LGE (-11.8 ± 2.8 vs. -15.0 ± 1.7%, P < 0.001). Multivariate analysis showed that GLS was an independent predictor of %LGE (standard coefficient = 0.627, P < 0.001). During a mean follow-up period of 42 ± 12 months, five patients had cardiac events. When the patients were stratified based on the median level of GLS (-12.9%), all events were observed in the worse GLS group (P = 0.018).
CONCLUSION: These results suggest that global 2D strain might provide useful information on myocardial fibrosis and cardiac events in HCM patients with normal chamber function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271116     DOI: 10.1093/ejechocard/jer318

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  56 in total

1.  Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype?

Authors:  Paco E Bravo; Hong-Chang Luo; Iraklis Pozios; Stefan L Zimmerman; Celia Pamela Corona-Villalobos; Lars Sorensen; Ihab R Kamel; David A Bluemke; Richard L Wahl; M Roselle Abraham; Theodore P Abraham
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-06-14       Impact factor: 6.875

2.  Relationships of left ventricular strain and strain rate to wall stress and their afterload dependency.

Authors:  Daisuke Murai; Satoshi Yamada; Taichi Hayashi; Kazunori Okada; Hisao Nishino; Masahiro Nakabachi; Shinobu Yokoyama; Ayumu Abe; Ayako Ichikawa; Kota Ono; Sanae Kaga; Hiroyuki Iwano; Taisei Mikami; Hiroyuki Tsutsui
Journal:  Heart Vessels       Date:  2016-10-12       Impact factor: 2.037

3.  Global longitudinal strain and left atrial volume index improve prediction of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy patients.

Authors:  Philippe Debonnaire; Joep Thijssen; Darryl P Leong; Emer Joyce; Spyridon Katsanos; Georgette E Hoogslag; Martin J Schalij; Douwe E Atsma; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan
Journal:  Int J Cardiovasc Imaging       Date:  2014-02-06       Impact factor: 2.357

4.  Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD.

Authors:  Rafael Kramann; Johanna Erpenbeck; Rebekka K Schneider; Anna B Röhl; Marc Hein; Vincent M Brandenburg; Merel van Diepen; Friedo Dekker; Nicolaus Marx; Jürgen Floege; Michael Becker; Georg Schlieper
Journal:  J Am Soc Nephrol       Date:  2014-04-03       Impact factor: 10.121

5.  The prognostic value of standardized reference values for speckle-tracking global longitudinal strain in hypertrophic cardiomyopathy.

Authors:  Gregory R Hartlage; Jonathan H Kim; Patrick T Strickland; Alan C Cheng; Nima Ghasemzadeh; Maria A Pernetz; Stephen D Clements; B Robinson Williams
Journal:  Int J Cardiovasc Imaging       Date:  2015-01-14       Impact factor: 2.357

6.  Heterogeneity of longitudinal and circumferential contraction in relation to late gadolinium enhancement in hypertrophic cardiomyopathy patients with preserved left ventricular ejection fraction.

Authors:  Keita Sakamoto; Noriko Oyama-Manabe; Osamu Manabe; Tadao Aikawa; Yasuka Kikuchi; Harue Sasai-Masuko; Masanao Naya; Kohsuke Kudo; Fumi Kato; Nagara Tamaki; Hiroki Shirato
Journal:  Jpn J Radiol       Date:  2017-11-09       Impact factor: 2.374

7.  Changes in Bi-ventricular Function After Hematopoietic Stem Cell Transplant as Assessed by Speckle Tracking Echocardiography.

Authors:  Stuart Covi; Yaddanapudi Ravindranath; Ahmad Farooqi; Sureyya Savasan; Roland Chu; Sanjeev Aggarwal
Journal:  Pediatr Cardiol       Date:  2017-11-01       Impact factor: 1.655

8.  3-Dimensional regional and global strain abnormalities in hypertrophic cardiomyopathy.

Authors:  Alessandro Satriano; Bobak Heydari; Namrata Guron; Kate Fenwick; Matthew Cheung; Yoko Mikami; Naeem Merchant; Carmen P Lydell; Andrew G Howarth; Nowell M Fine; James A White
Journal:  Int J Cardiovasc Imaging       Date:  2019-05-29       Impact factor: 2.357

9.  Clinical and imaging description of the Maron subtypes of hypertrophic cardiomyopathy.

Authors:  Patricia Reant; Erwan Donal; Frederic Schnell; Amelie Reynaud; Magalie Daudin; Xavier Pillois; Marina Dijos; Mathieu Landelle; Jerome Peyrou; Claire Cornolle; François Laurent; Michel Montaudon; Raymond Roudaut; Stephane Lafitte
Journal:  Int J Cardiovasc Imaging       Date:  2014-11-25       Impact factor: 2.357

Review 10.  The most important publications of the past year in echocardiography.

Authors:  A Farkhooy; F A Flachskampf
Journal:  Herz       Date:  2013-02       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.